IMG_E1413

コメント

  • コメント (10)

  • トラックバックは利用できません。

  1. The “trailing effect” in vitro can make susceptibility interpretation for Candida challenging.

  2. Diflucan penetration into the CSF is excellent, a key pharmacological advantage.

  3. Activity is pH-dependent, with optimal efficacy in neutral to slightly acidic environments.

  4. “Fluconazole-refractory” candidiasis is a specific clinical entity in advanced AIDS.

  5. Diflucan is not first-line for invasive aspergillosis under any circumstances.

  6. Resistance to Diflucan is a growing concern, particularly with Candida glabrata and krusei.

  7. Rifampin induces fluconazole metabolism, potentially leading to subtherapeutic levels.

  8. Diflucan is a model of predictable pharmacokinetics within the azole class.

  9. Therapeutic drug monitoring for Diflucan is not routine but can guide therapy in complex cases.

  10. Resistance to Diflucan is a growing concern, particularly with Candida glabrata and krusei.